SSGJ-608 achieves 92.7% to 95.1% PASI75 response in moderate-to-severe plaque psoriasisNew injection shows promise for moderate to severe plaque psoriasis

Frontiers in Medicine Published June 10, 2026 Study authors: Lin Cai, Jing Chen, Liming Wu, Xinsuo Duan, Guoqiang Zhang, Yumei Li, Litao Zhang, Lanying Qin, Tong… DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider SSGJ-608 as an effective option for moderate-to-severe plaque psoriasis based on high PASI75 response rates at 12 weeks.

This phase 3 randomized trial evaluated the efficacy and safety of SSGJ-608, a novel anti-IL-17 monoclonal antibody, in 770 patients with moderate-to-severe plaque psoriasis. Patients received subcutaneous injections of 80mg SSGJ-608 every two weeks (after a 160mg starting dose) or 160mg every four weeks. The primary outcome was PASI75 and sPGA 0/1 response rates at week 12.

At week 12, PASI75 response rates were 92.7% in the 80mg Q2W group and 95.1% in the 160mg Q4W group. sPGA 0/1 response rates were 80.3% and 79.0%, respectively. Secondary outcomes including PASI90 (81.0% vs 82.3%), PASI100 (49.4% vs 47.5%), and sPGA 0 (49.4% vs 47.3%) were also comparable between groups.

Safety data showed a favorable profile with no new safety signals. Reported adverse events included hypertriglyceridemia, upper respiratory tract infection, hyperuricemia, increased alanine aminotransferase, and hypercholesterolemia. Serious adverse events and discontinuation rates were not reported.

Limitations include the lack of a placebo comparator and short 12-week follow-up. The study did not report p-values or confidence intervals for the comparisons. Practice relevance: SSGJ-608 was highly effective, especially in patients previously treated with anti-IL-17 therapy. Clinicians should consider these efficacy data but await longer-term and comparative studies.

Living with plaque psoriasis can mean dealing with persistent, itchy, and inflamed patches of skin. A recent trial looked at a new injection called SSGJ-608 to see if it could provide relief for those with moderate to severe cases of the condition.

In the study, 770 people received the treatment in two different dosing schedules. By week 12, over 90 percent of patients saw significant skin clearance, and about 80 percent reported that their skin looked much better. The results were consistent across both groups, showing that the medicine worked well regardless of whether it was given every two weeks or every four weeks.

The treatment was well tolerated by the participants. While some people experienced common issues like upper respiratory infections or changes in blood fats and cholesterol, no new safety concerns were flagged. This treatment showed particular promise for patients who had already tried other types of therapy.

What this means for you:

The injection SSGJ-608 showed high success rates in clearing skin and improving appearance for psoriasis patients.

Study Details

Study typePhase3

EvidenceLevel 2

PublishedJun 2026

View Original Abstract ↓

SSGJ-608 is an anti-interleukin-17A monoclonal antibody with high specificity and high affinity and has shown promising efficacy in treatment of moderate-to-severe psoriasis in preliminary trials. This multicenter, randomized, open-label, phase 3 trial aimed to further evaluate SSGJ-608 at different dosing intervals (80mg every two weeks and 160mg every four weeks) in patients with moderate-to-severe plaque psoriasis. A total of 770 patients with moderate to severe plaque psoriasis were randomly assigned (1:1) to receive subcutaneous injections of 80mg of SSGJ-608 every two weeks (Q2W) after a starting dose of 160mg at week 0(608A group), or 160mg of SSGJ-608 every four weeks (Q4W) (608 B group) for 12 weeks. Efficacy was assessed by PASI75 and sPGA 0 or 1 response rates at week 12 as co-primary endpoints, and proportion of patients who achieved PASI90, PASI100 or sPGA score of 0 at week 12 as secondary endpoints. The safety profile was also evaluated. At week12, the proportions of patients achieving PASI75 (92.7% vs. 95.1%) and sPGA 0/1 (80.3% vs. 79.0%) were comparable between the two SSGJ-608 dose regimens. The PASI90, PASI100 and sPGA 0 response rates were 81.0% vs.82.3%, 49.4% vs. 47.5%, and 49.4% vs.47.3% in the 608A group and the 608B group, respectively. In the subgroup of patients previously treated with anti-IL-17 therapy, SSGJ-608 also achieved high clinical response rates at week12. The most common TEAEs were hypertriglyceridemia, upper respiratory tract infection, hyperuricemia, increased alanine aminotransferase and hypercholesterolemia. Both treatment groups demonstrated a favorable safety profile and no new safety signals were identified. SSGJ-608 was highly effective for treating patients with moderate-to-severe plaque psoriasis at 80mg Q2W and 160mg Q4W in a larger population, especially in patients previously treated with anti-IL-17 therapy, and exhibited a favorable tolerability profile in Chinese patients with moderate-to-severe plaque psoriasis. https://clinicaltrials.gov/, identifier NCT06299982.

SSGJ-608 achieves 92.7% to 95.1% PASI75 response in moderate-to-severe plaque psoriasisNew injection shows promise for moderate to severe plaque psoriasis

Study Details

Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment

Study checks how well pain scores track joint damage in psoriatic arthritis patients

Clinical research that matters. Delivered to your inbox.

SSGJ-608 achieves 92.7% to 95.1% PASI75 response in moderate-to-severe plaque psoriasisNew injection shows promise for moderate to severe plaque psoriasis

More on Plaque psoriasis

Study Details

Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment

Study checks how well pain scores track joint damage in psoriatic arthritis patients

Clinical research that matters. Delivered to your inbox.

Related in Dermatology

From Other Specialties